Ugandan President Yoweri Museveni has recently advised the public to avoid shaking hands, casual sex and do-it-yourself burials in order to lessen the risk of contracting the deadly Ebola virus after an epidemic killed 14 people and put many more at risk. the President has given the advice after scared patients and health workers ran away from a district hospital located in rural western Uganda where many patients of Ebola were being given treatment and as the authorities tried to alter people’s behavior to stop the virus from spreading.
Pfizer Inc. (NYSE:PFE)
Shares of Pfizer Inc. (NYSE:PFE), the world’s largest drug developer by revenue, declined after it reported a fall in second-quarter profits on decreasing sales of its top-selling cholesterol drug, Lipitor, and broad rivalry for its glaucoma pill Zalatan.
According to a Thomson Reuters assessment of analysts, Pfizer Inc. will report earnings of 54 cents a share, dropped 9.3 percent from 60 cents per share in the year-earlier quarter. Revenue is projected to slip 12 percent to $14.93 billion from $16.98 billion.
Pfizer Inc. (NYSE:PFE) plunged -0.48% and closed at $23.71 with the total traded volume of 23.79 million shares. PFE has earnings per share of $1.06 and it gained 4.37% return on assets, 9.56% return on equity and its return on investments was 5.14%.
Merck & Co., Inc. (NYSE:MRK)
Merck & Co., Inc. (NYSE:MRK) reported its Second quarter results that is above than Wall Street estimates just as broad competition is preparing to start devastating sales of its top-selling medicine.
The world’s third-largest drug maker by revenue preserved its profit estimate despite net income declining 11.4% as higher sales were compensate by adverse currency rates and purchase and restructuring expenses. Still, adjusted profit surged 9%, and it was Merck’s sixth straight quarter where revenue and adjusted income both gained.
Shares of drug maker Merck & Co., Inc. (NYSE:MRK) slipped -1.36% and closed at $44.48 in last trading session. Its overall traded volume was 11.48 million shares. Its outstanding shares are 3.04 billion with the total market capitalization of 135.29 billion.
Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) declined 0.10% with the closing price of $69.45. The overall volume in the last trading session was 6.87 million shares. Its fifty two week range was $59.08-$60.70. The total market capitalization remained $190.74 billion.
JNJ is ahead of its 52 week low with 21.92% and its last month price volatility remained 1.15%. Its beta coefficient was 0.55 with a target price of $74.50. Company’s current year earnings per share grew with 27.11% while the five year EPS growth rate was +12.65%.